Anduril just crossed $1 billion in revenue. Neuralink has zero. Both are now in the same Pre-IPO fund. That divergence is the most interesting data point in this entire deal.
MSX Pre-IPO Phase III has added Neuralink and Anduril to its portfolio. The narrative writes itself: AI's two extremes, the human mind and the modern battlefield. But narratives don't pay LP distributions. Let's look at what the data actually says.
Context: Two Companies, Two Timelines
Neuralink is still in clinical purgatory. Three patients implanted. FDA breakthrough device designation secured. The CONVOY study, approved in November 2025, will test whether a paralyzed patient can control a robotic arm with their thoughts. The technology is real. The revenue is not.
Anduril is a different beast entirely. The Lattice software platform has become the operating system for modern defense. Ghost 4 drones. Dive-LD autonomous submersibles. Roadrunner missile defense. The December acquisition of UK-based Callum for $1.3-1.4 billion adds 3D-printed drone manufacturing to the stack. Revenue hit $1 billion in 2025, up roughly 150% year-over-year.
MSX is betting on both. That's the headline. The question is whether the underlying math supports the bet.
Core: The Valuation Gap and What It Tells Us
Let me be direct about the numbers. Neuralink's last private round valued the company around $5 billion. Market chatter suggests the next round could hit $8-10 billion. Anduril raised at $14 billion in 2024, with expectations of $25-30 billion in the next round.
Here's what those numbers mean in practice. Anduril trades at roughly 14-28x forward revenue. Palantir, the closest public comparable, trades at 30-50x. Anduril's multiple is actually reasonable, if you believe defense contracts will keep flowing. And they will, as long as the US and its allies keep modernizing.
Neuralink's valuation is pure optionality. Zero revenue. Zero near-term path to revenue. The FDA's De Novo or PMA approval is still 12-24 months away, assuming no safety setbacks. The pricing model is undefined. The competitive landscape includes Synchron's less invasive Stentrode, which already has 10 human implants and a safer risk profile.
Based on my experience auditing the 2020 DeFi Summer, I've seen this pattern before. A narrative premium that outpaces fundamental progress. The question is always timing. Neuralink could be a $50 billion company by 2030. It could also be a cautionary tale about regulatory delays and electrode degradation.
The On-Chain Signal Nobody's Watching
Here's what the market is missing. Anduril's defense contracts are the closest thing to a smart-money signal in this deal. The $250 million DIU contract for large-scale expeditionary operations. The UK Ministry of Defence deals. The OpenAI partnership for counter-UAS systems. These aren't speculative bets. They're paid deployments with clear milestones.
Neuralink's signal is different. The CONVOY study is the first real test of whether brain-computer interfaces can move beyond cursor control. If the robotic arm trial succeeds, the medical pathway opens. If it fails, the narrative collapses.
Follow the smart money, not the hype. The smart money here is in Anduril's contract pipeline, not Neuralink's press releases.
Contrarian: The Correlation Trap
Everyone assumes Neuralink and Anduril are complementary bets. Human augmentation versus human replacement. Both point toward AI becoming an autonomous agent. That's the story MSX is selling to LPs.
But correlation isn't causation. These are two completely different risk profiles. Anduril's risk is political: defense budgets, geopolitical shifts, export controls. Neuralink's risk is biological: electrode failure, immune response, signal degradation over time. One is a policy risk. The other is a physics risk.
Exit liquidity is someone else's entry. The Pre-IPO fund needs an exit in 2-3 years. Anduril could IPO by 2026-2027. Neuralink's timeline is less certain. If FDA approval slips, the fund's holding period extends, and the return math breaks.
There's also the ethical overhang. Neuralink's invasive approach raises questions about autonomy and identity. Anduril's autonomous weapons trigger concerns about lethal autonomous systems. These aren't just philosophical debates. They're regulatory risks that could delay approvals and contracts.
The Blind Spot
Everyone's focused on the technology. Nobody's asking about the valuation mechanics. Pre-IPO funds typically target 3-5x returns. To achieve that, Neuralink needs to IPO at $25-40 billion. Anduril needs to IPO at $75-100 billion. Those are aggressive assumptions for companies with zero and $1 billion in revenue respectively.
Code doesn't care about your feelings. The market will price these companies based on execution, not narrative. Anduril has execution. Neuralink has promise. Those are different assets.
Takeaway: The Signal to Watch
Over the next six months, watch two things. First, Anduril's contract announcements. If the pipeline keeps growing, the $25-30 billion valuation is justified. Second, Neuralink's CONVOY study results. If the robotic arm trial shows meaningful progress, the $10 billion round makes sense. If either stalls, the Pre-IPO thesis weakens.
Transparency is the only security. The data will tell you which company deserves the premium. The question is whether you're willing to wait for the evidence.
The real signal isn't the headline. It's the contract pipeline and the clinical data. Everything else is noise.
